ENTX - Earnings call transcript Q2 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone to the Entera Bio Second Quarter 2019 Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-an-answer session. you. Thank LifeSci begin from conference you Advisors, Yedid the may call. Bob

Bob Yedid

call. and welcome you, to Thank the

Joining the of this was today A results Officer; and me for on Yaacov-Garbeli, morning. press Phillip Chief Gridley, Dana quarter financial Schwartz, Executive release our the announcing our and Interim second issued President our Research Entera's Development; call and CFO. is operating Adam XXXX of

by yet our seen the those session. site it, we will call a For have and financial you question-and-answer of is in of who this business with be the site. our and Investor www.enterabio.com, results not Section at SEC's Web followed you at posted morning, available will On which share update it also will Web this be

statements business These that include strategies or Litigation meaning making call, the of be or Securities statements and XXXX. During today's financial, Reform performance we'll of operating, within the Act our expectations. future forward-looking address Private

Exchange clinical based and candidates, materially regulatory expectations encourage cause actual management's are investors risk information those not SEC make could future August as the and with on Form decisions we our in business and otherwise. only the uncertainties are Forward-looking future to current this developments, and financial obligation on call described on events, and trials, our We position, information, approvals, filings. our as filings our of undertake in those may or that and the position call any filing and report all well of timing limited differ contemplated risks forward-looking to of this clinical no provided and statements the account and is new Securities our involve risks provide statements. XX-F on XX, by we the timing XXXX, of as uncertainties results, statements in today, include to but update on we or from conference significant factors and Those read of utility All annual our those to product the and conduct likelihood Commission. intellectual property beliefs,

be the will to is Executive Adam? recorded over those being Entera's today's turn Officer, I now prepared With advised please remarks, call Adam Finally, Chief and that call Gridley. webcast.

Adam Gridley

Thank and examples of medical the Amgen research delivery look all and are there's truly for to was the of disease vision board cases very to evolution. the team. join company, of as steps fully what delighted stepping reputation oral in a the a by Bob. with solve company's you, I converting and to the much our dearth license as and the senior can and such part acute at whether take a into it as and hypoparathyroidism senior company's as age Entera our some significant me directors, a of opportunity be collaboration Whilst Schwartz, compliance his to to to to for strong daily clearly exciting needs. am His strong and delivery directors welcome, developing Dr. of global special organization warm for A believe therapeutics agreement molecules co-founder public of a requires the to accelerate him in the December to and I a of novel this the look with entrepreneurial historically recent Phillip Entera products R&D, prevent were thanks commitment indication unmet board I President research-based or attracted time to transform evolution. with board the organization to from of tremendous novel The heritage to transition well scientific we what forward this and addition announced pill efficacious biologics osteoporosis. that injectable would some challenges to old in advisors, taking are forward a I mechanisms

within the entry this a leading community satisfactory seeking not who to disease provide and pharmaceutical treating game better is due our of a Our biotechnology are the population zero-sum patients Instead, and to a delivery partners to an injectables. their are symptoms This solutions. options. competitive all patient and state opportunity expand is lack not demanding or to

presence of company, realized turned I made unleashed in board be that potential Toledano with our satisfactory Sean of The solution or the other that and Chairman the by in we into was Roger, value therapeutic Lastly, Faith we the the not and strong enable patent once management back bolstered talented Jerry two yet to Arthur. investors Ostrov created to of as itself. to directors, then believe oral platform Ellis. pipeline, significant This including and and development medications our addition molecules executive with XXXX evolve or team protected the could with commitment as addition independent Miranda Jerry be This addition our has of and a there Board; and of be available. XXXX proteins started fully is the within our may our in the have new investments is believe Hillel, Charles and grow promise Lieberman markets and

shareholders. the calls with a end, and to platform. funded growing visible is the manner We and regular for story in creates a pipeline, of and realize investor enabling the in investors, organization cadence investors, and this and going investors compelling partners, of conferences to the at potential opportunity To tell the manner, that ensure in adequately Entera's us be our presence to to that a what quarterly responsible a team, existing thus, invest responsibly before new this will continue Today to this will is of analysts and forward. our value the grow us first potential full

for associated lead agenda call of our include our opportunity So and programs. upcoming development market today's for milestones, the will overview an programs, the

review operations, and speak financial and business then will then efforts we development briefly remarks, concluding current call for following the session. before will open to We our we our question-and-answer relations a investor

technology effective of protease working parathyroid enhancer absorption the or of and in highly through allows This in facilitated and which the tract. believe the our the are therapeutic do was fashion and of platform with was The with with the in fund later technologies molecules well others reminder oral we drug to develop have ensures to and molecules Let's potential hormone that these normally those only their to strategy the be inhibitors consistent drug. molecule. was complementary as other molecules delivery collaborations. molecules be Entera, other efforts two validated as for delivery a combination of in Entera. proteins delivered. with lead The he combination Phillip early delivery and walls of allows facilitating biologic this do. large GI as product as a on DNA of and of external back and can what the those start number by pipeline small applied underlying discovery The maximizes partnered founded XXXX tract internal technology validated PTH by We as effect consistency the well the GI molecules with a technology to efficient who we of protecting quick we absorption our The company

delivery such pipeline, decision osteoporosis need without unmet as cases market in compliance relative multiple our and was the sizes to of the are able efficacy informed oral Now and to by substantially chose where the alternately to of in we daily. our for poor case the due the hypoparathyroidism and internal as therapeutic indications injections improve of we

will I our substantial these So, our patients. product let's Phillip? to to review programs, an to status overview may provide needs, start of with candidates. the two market and turn where our Phillip the benefits lead of solution

Phillip Schwartz

the if primary (b)(X) endpoint, incidence will the really drug in plans Phase into much, for soon provided apply been pre-IND I development produced It's rather past for of this to approval a development week the the the should have Based high a this required from enjoyed warm FDA this feedback osteoporosis, fracture XXXX, of that as density support our potential XXX to believe drug. confidence, and our is We Adam, candidate with you, with guidance confirmed move EBXXX. In osteoporosis. and a degree pathway new funding we I as discussion of to treatment than pathway approval begin and Thank FDA like give FDA Adam. our I X EBXXX a very after and really meeting, working on registration use with XXXX substantially the X him from you meeting late for guidance marketing to commercialize lead that EBXXX pathway positive the to time would In or Phase allow formal as intend recent to received XXX and working a the the application successful, BMD NDA. studies to FDA guidance product. mineral trial with in welcome for reduce of would the and of half. we is a possible Utilization and bone like greatly completed. really pleasure for and we meeting a Entera meeting, regarding accelerated the our us the the (b)(X) in the the our have for

three Phase initiated initiated XA for registration us study controlled BMD product. evaluating the X large commercialize July announced with discussions in the endpoint study pharma to trial XXX would different dose short the of Although have allow that patients. in utilization enrollment EBXXX our we double-blind conduct as a and primary doses placebo in we the on We a to Phase own, ranging to conduct partners enabling

both treatment density a optimal safety safety and of Phase markers as into we the analyze a pivotal number of and doses endpoints. X advance well study. last mineral as will bone will EBXXX We evaluate The will determine bone months to period six and

favorable study, we point known has like Phase that X Eli understood with an PTH Lilly Forteo, multi-center period. PTH, study, a then the that meaningful, would Assuming X.X I'd months over data longer also to readouts data XX Thus, as from is as in of in well marketed had oral BMD single in million is will PTH six greatly one trial. non-inferiority head-to-head Entera's Forteo larger, treatment a by which probability of we a of term drug a very well-tested to worldwide. exceptionally the generated conduct and the and EBXXX. through out very this as comparing outcome predictive market this XX, We increase XXXX bone that believe data approval with been historically utilized of drug upcoming the be short-term over successful people efficacy believe been

people of million National for of osteoporosis than United more at in incidence to fractures. elderly. a risk therapy patient are two pain on briefly the current say and increase one treatment The there lead Osteoporosis that development lack an worldwide estimate in additional can hip disease and Osteoporosis issue The is X% than Osteoporosis one of to touch form here affects primarily XX these fold the compliance. with three suffering system XX of is articles of therapy. more treating less osteoporosis. greater this receiving to osteoporosis. immense The with four-fold times The less increase of there estimates caused healthcare nothing just of XXX academic cost are Foundation the Foundation Let's million are and to that is osteoporosis and numerous International preference fractures than the therapies patients of therapy, million high the fractures States, and that therapy, The with cost and the cost any many or by silent than is a in the of these fractures. problem

the have annually. portion in the market as drug may $X.X with feel with potential marketplace, China revenue incidence, most fact of effective not The many with some percentage an of is they're at not a people drugs an injectable now With compared $X.X Despite a income the of healthcare. generate as that pill, market the only take billion $XX injections, estimated pill efficacy to our to despite take by to the willing osteoporosis, a grow willing for expect the the minds patients the tiny increasing million daily EBXXX of spent by industry serious we growing and billion in as such U.S. of these in or thus, As excellent really which do exist, providing comparable better low patients injectable is sick, patients osteoporosis the XX much treatments. mind, a has once not are sources alone respectively treat to disease, rate osteoporosis therapies does to injection and solution. rarely their to elderly solution, approximately disposable in substantially on billion. top that treatment

Next, the the second bloodstream results orphan and PTH first PTH November treatment from drug known studies a active as day. almost activates oral of biological for well XX-hour In disease regulate. proprietary vitamin the we'll is impact the PTH patients about and hypoparathyroid X and positive for hypoparathyroidism. pharmacodynamic we our to confirming the pathways into to levels of and that talk that Phase EBXXX, delivered is shown in reported and just has pharmacokinetics XXXX, PTH level of calcium phosphate, urinary induced effectively XX% serum calcium, as positively decrease D, one Oral part treated

with the included regimen treated in PK/PD oral for of evaluated part a PTH second of times drug available administered patients study of this which the The treatment day, high and were Natpara, low hypoparathyroidism. also dose three a commercially has norm and a

data We conference clinical and our will of for trials. XXXX which of medical September a expect provide to the present anticipated this input in design results pivotal

provide PTH a may hypoparathyroidism States. is injection, kidney produce in dementia. in available failure, Hormone approximately the the high in For may part osteoporosis conditions since kidney calcium which parathyroid biological of produced low potentially stones, on activity. also sufficient to the a commercial to form which the even Shire, better program, compared the perspective believe affects These been the deficiency but a in events, of and PTH blood is including Like will efficacy better severe last XX,XXX which cardiovascular very commercially amounts to or vivid has therapy of of hyperphosphatemia. hypoglycemia, of condition is hormone the available Takeda. oral our compliance, replacement number candidate patients marketed of failed phosphorus Due we hypoparathyroidism parathyroid levels market, United in exhibit case, rare XXXX. serious as the by now and glands cause PTH of abnormally people levels in Natpara

Union. Importantly, awarded United Entera's has front. business been to European to orphan the now Relations the cover States drug progress on turn I'll development PTH Adam? our in the oral and candidate both Investor the over designation call Adam and

Adam Gridley

Thanks, Phillip.

over the opportunity, programs To three number business our earlier, on our coming development years. opportunity lead exploratory of of potential As are leading ongoing narrow discussions goal I to the areas for substantial, programs of is focus on noted both our a our and and is main and execute programs are pharmaceutical the focus and frame there biotechnology companies.

are First growing patent are well the those companies with leading injectable facing franchises now of biosimilars. that expirations threat as as

proteins which of to have to might developed the with which biologics we're These some than similar of In development platform, be oral injections efficacy, great potential drugs a a have medical by effectively discontinued intriguing of may been they're cannot usable. Secondly, but drug technical are enabling have work been utilized reasons. and this identified development the proven number that way, Amgen, for pathway as many not with in that cases our delivery in other interest is be frequently our companies partners. and otherwise

of believe technology. biopharma there efforts for a was our deals joining Part we China broaden deals in the Lastly, for regional XXX of number applications, currently EbXXX companies and example, certain we to rapidly and where or a global evaluating certain are company my the accelerate other develop license to commercialize may that these of products. our are platform

cases, detail indications, when can't bit ongoing While dialogue. to our partnership target regarding with be license least formal to months. XX molecules agreements, variety such parties Conference these a we Israel from material outcome be the or significant continue to can we we parties talented we interest additional platform. on suitability with the transfer work Bioindustry At with our in discussions and for for move and June, next certain companies. you in team Entera, our of lead where each technology will agreement to share our with in one and, leading may here the in those R&D confidential of Those able predict to work technology a goal exactly studies, proteins many will our had in at may to to how a of of XX evaluate Depending Philadelphia inbound the

is December Moving and this nicely the deal, on since Amgen progressing to XXXX.

Both conducted, successful a jointly and have continue forward studies. frequent we as We have planned, preclinical completed teams of quickly possible. meetings number as and move project to

reimbursement expenses. As for a all reminder, milestones to the and aggregate preclinical up deal XXX million in these includes

tremendously programs. I'm an are about opportunities into clinical best the registration global area to and and that Lastly, leverage excited experience our development

China leverage recent for regulatory entry into pathway function in development may into development history a rapid osteoporosis positive as of to a allow expedient the of long reforms us more the Our China.

on markets In has are to indications the to diligence, therapeutic working leading a strong ongoing China, today's and expect are future potential products after, the regarding have develop the sought there completing we with reputation partly the becoming the and retained over political environment, in that trade highly addition, to In Israeli partner. calls. and our partly where arisen partners both and firm the our have may segments, with theme, last we additional updates due regular of technology with development. science and technical due that and partnerships months, our unique several interest strength progress In business inbound market to to or we Chinese assist are

story company our Now a appreciate Investor by We our and proactive has and frustration performance, approach be and a strategy. historical to there's will we that our regarding stock taking let's supported price more Relations investors. our largely of Entera Historically, relatively quiet turn been our of communicating vision. level holistic

development be our Relations strategy and public a in on are internal build relations will our executing engage conducting concerted by non-deal investors in but market. we implemented parallel, regular clinical and first activities, presence to the the but focused business road will programs, on with ongoing We shows Investor

We front coverage, sell And be in on regular in develop presence part based as quarterly analysts, online equity us on appropriate dialogue States, will particularly be of other United pipeline deep a research to we progress of side tools team, research our area, calls our lastly with material We'll the finance, other a there's shareholders. our Boston and in a engaging relationships and you additional Investor platforms. supporting development website, variety complemented talent. in press and seeking be today, investing building updates, updates in by Relations will out with business the the and where on to my and our particularly find releases,

will United We discuss the our our to turn continue the I development building and capabilities our out States. in point, clinical over development and At to this financials. in teams Dana Israel, will call

Dana Yaacov-Garbeli

you, Adam, and morning good Thank everyone.

the statement licensing appear six to provided services and months filed June of Revenue today. three quarter the XX, Our the results in the months under financial from ended Amgen revenue. XXXX $XX,XXX were for XX, six for XXXX end June earlier our

balance manufacturing, Our operation million. XX, June for $X.X ended the and evaluating to months of Development expenses, expenses. XX, Centers loss months salary comprised XX, insurance will liquidity million, XXXX session. we salary before total remarks million go XXXX, and General the to was million six Adam the question-and-answer June are $X.X capital related increase find cash and working of we were ended Administrative for Adam. which and expenses, six for materials, of we for June I our to concluding of DNO June months related $X.X XX, out the back XXXX were Research XXXX and turn trials call measures the for the now will operating XXXX and legal other need. the $X.X clinical end clinical compensation, expenses. comprised share-based six variety including and our was and of largely expenses largely Total of believe

Adam Gridley

opportunity Thanks, this. us just come Dana. appreciate appreciate what weeks as before you everyone's We ongoing I've is well in the and short realize as with support only to few if required broad Entera a

in developing rapidly cohesive share we'll business Investor months. be will that We and development, with development, you the a strategy coming product Relations

articulate value, ingredients background, My set market strong our with commitment board with realizable and leading to a All substantial of platform. experiences shareholders members validated strategies. drive clearly can to markets be of management need and technology responsibility create are milestones the the believe and patients addressed and we R&D here with value tremendous that and these our team, is large our diverse based proposition each to unmet on

we manner this outside to We will team include of allocate for only lead milestones of lead if over of years of and true dose developed compelling and fund EBXXX. PTH of In of lead we the have our we is value study an remiss for enrollment next would those oral candidates, summary, of the version our help accordingly our company maximize for our for the when important platform. then programs, ranging candidates. Phase responsible well resources dose the EBXXX, for Candidly, series technology couple in of X a opportunity be programs. our both ranging already seen completion filing the creating study data INDs These results a

believe these the in we'll for any to forward in pipeline we reassuring our which further global not of bigger develop programs. our up reporting an opportunity, the we Operator, be and with and are open one on partnerships, have to delivery look have We'll Entera up our impact non-dilutive rapidly In companies biotechnology the several to progress open leading even calls, outside rapidly please we PTH future line oral lead summary, or repositioning the we Lastly, business but development and of engaging development now capital industry. patients on potential milestones could and bring for partners, line. questions. just a as

Operator

question-and-answer now you. be Instructions] [Operator Thank conducting Thank you. session. We'll the

of the question. Maxim your is Please Quibria with proceed question from Group. coming Naureen First with line

Naureen Quibria

Gridley your Entera. Adam with Congratulations new morning. good on role Hi, to

landscape this, the you So but I current competitive alluded know, perhaps, the you could osteoporosis, just to on wondering, share space. your anabolic you on was particularly view

coming up have shortly that you PDUFA who's injectable got biotech Evenity, one there's presently also Forteo, in April. Amgen in generic is approved Forteo, got just an October, their You've

these you this how EBXXX all see So, of have you -- in Entera you obviously with light EBXXX landscape? could do competitive developments, perhaps differentiate in

Adam Gridley

is you to some provide this there. kind and feedback and then start, over I'll for Hi, Adam. Naureen, it the to happy turn Phillip Thank welcome, to

enthusiasm So I market to for actually think our the continues grow.

very for exists still I as signaled patients, available we release the very script, here much osteoporosis, press that injectables. but who and there's need highlighted in small to entrants could women think issues treating of a be hesitate with the both our the their competitive just percentage and do this compliance

very actually such So, for such it's such be in market an we the think EBXXX, if that to use compliance aren't we favorably, a think to that well this as favorably. opportunity, you'd symptoms perspective, dealing would surgeons as want seen hard we very that able and this able both improve fact also perspective, of an a would as but to were do you Phillip, can oral this from they presentation treat with grow anything ease heard a to with disease, those immediately and from patient that from that be add? we've our

Phillip Schwartz

I concur everything said. thanks Adam very that Adam. Yes, with much, Yes, would

revenue, from treated and less like In utilized operates. throughout is though Adam most exceptionally profiles, are has or few of preventing driver very, primary take as osteoporosis some safety with amount it oral the of one very treated, with relatively specifically people mentioned, the that it from form addition the of best believe even well-tested world treated oral well of is version market. utilizing patients patients, of how the injection form therapy. Forteo understood that I Forteo very is believe, has an Forteo, of who to to essentially of The infusion than, and it's EBXXX, any add and currently it. relatively or making XX% which large treated those expand approximately X% a market that, Currently of the population I'd We

silent one the medication of to for oral or disease. someone therapy is clearly, an not whether adopt whether major this or will it's not, So, drivers

are a specifically as mentioned, these us Adam osteoporosis for market, relatively Evenity actually as very many the of proportion generic being of that development think some Additionally, and agents, Forteo's actually small hit treated is and anabolic well really because positive at population more these will think very, the potential I being all, important new treated of drug the osteoporosis a I how serious of I goal disease treated think just people osteoporosis, for the increase significantly amount and given which it get their as to as for have awareness, our is. to increase the the drugs is for patients

Naureen Quibria

results Great, perhaps elaborate And your and you bit you the Thank enrollment have you. know, actually will to initiated, that's more study? helpful. actual be XB Phase that How the you study could little program, with of the the you Phase How think regards you think inform pace a may in? on the do do X design?

Adam Gridley

Thanks, Naureen.

So, I'll start.

sites a basis was some patients input or have based the we'll and the and six a so, at study of on complete out collecting the data we be starting with enrolling, that rolling screening month data, over the we from in that expect months. readouts the coming all with of three course are marker three currently As at on we data months bone The patients some number first density way bone the the in designed of approximately XX% will then which of XXXX enrolling coming mineral of the and will followed in we significant just agency, started have by of patients, last we and now, noted, quarters. enrollment is

on to study dose-ranging be from really X X. we'll of Phase the to is dose historical to Phase studies fracture add help very solid, data design. then Phase appropriate same the like inform believe the the feedback the the a that? that the We unlike very agency that well-defined, you'd anything and Phillip, this some some using of for X So, is inform of intended based the design to

Phillip Schwartz

Yes.

wanted a in we of that make with the inform we think, reaching were think adequately on of separate very very, as believe about question be our to that go really that we statistically right all may primary not the we'd treated. have is low is where the each well. that dose, will doses. I Phase would threshold Naureen, our to that and how to We focusing sure at confirm patients in that concern now, your will currently trend, be a but ahead design this to designed case, but like strong trial X, And

say very and noise longer background data, data has would of predictive data, because Mineral valuable that bone BMD, a study. highly in very, this marker marker the small data is Additionally, the data the outcome I of and having incredibly relatively Bone bone be Density this will amounts

So, can X we be Phase additionally, understanding helpful study, of terms all data as exceptionally well. will of this power in that how

Naureen Quibria

again. helpful Great,

So, and you have final the data there September, full reported, you to with of would mention be program? your program, just mentioned question data was what regards but no steps the I in conference, next EBXXX the that for particular from wondering me that was

Phillip Schwartz

Excellent.

may data of regulatory will be help of peer as will on expect publication perspective the review full be dataset Mineral most a our typically and at presented that this will this we're data Society So, presentation. the is Research American study. that do also poster and where be Bone and We feature steps we will design a assembled Phase our next basis. how X from inform a for That a presenting

coming step look what that in you will should the this input the additional is expect and release, data from on next like. program us So, quarters of that

Naureen Quibria

me. from it That's you. thank Great,

Phillip Schwartz

Thanks, Naureen.

Operator

you. Instructions] line next proceed your from [Operator is Please with question. Our Thank [indiscernible]. of the question

Unidentified Analyst

taking for as taking helms well and Good congrats on the of morning, as questions, the the company. thanks Adam

Adam Gridley

Thanks.

Unidentified Analyst

time at blinded? EBXXX X and in remain My broken biomarker will month that sort my blind Phase no is the date you that When does the or for data, the three this -- question first -- study. trial first report the trial problem, be osteoporosis of

Adam Gridley

Excellent question.

So, the not data unblinded. be will

So continue per trial the at We'll some to measured blood and taking density remain do the well. discussions the patients to for protocol as by with endpoints per and three then mineral as and agency, months bone It's actually unblinded possible randomized. are with this the the tests. will six studies follow

nature robust making of conduct So not collection all the the very this sure We're will of data that to is be plan. that. by part the impaired the and sensitive

Unidentified Analyst

feedings, the the unblinded groups have two but of, or groups the between and breakdown that? three of we some will -- don't redid we data sort some So, finals, know get two

Adam Gridley

Absolutely.

So investors to sure have that interim want we our and to that process. ongoing be and instructive, naturally, we quite our patients will data think visibility make that actually

allow was And part business top line So the and both X not only engage Phase designed terms much from top And significant that then of very so that'll potential we to updates month will study. a patients, data. partners, protocol the of rolling be and interest definition. providing data, given basis six but the investigators, report of continue could then three with the on potential on us we design in then group to line FDA also the that, start out development we the to

is this original part plan we the So, all this. of as design

Unidentified Analyst

can be to of the say, follow-up limited have And that Amgen might maybe -- Amgen progression question, what regarding the just you future, of the program? any the general may but from you kind more you may know what's which one is that great. announcement for Okay, say, guidance have curious, you I collaboration,

Adam Gridley

our Sure, the the excellent of question. but And that with are correct, you confidential, very share program details matter. proceeding in is positive a we can are ongoing you collaboration Amgen

material and laboratories updates progress continue that any the a extremely and the they're color a that for additional far, made. get teams at think would been in Our bit provide doing coming to work very Phillip, over evaluating, that. positive, expect visibility that We Israel. are we've to with our as material pleased come updates in the been program quite regular Phillip to we quarters, and dialog we'll thoughts, first Thus of I further I'll provide… you collaboration has can both parties other any the and any then out ask of

Phillip Schwartz

would Amgen their Thanks, Adam. to experiments also well. just also add also doing facilities been as has in No, that I

we're I well. allowed that think as that to reveal

can Amgen this Additionally, additional say mentioned, evaluating this to and that agreement. I is constantly program. collaboration the We this that programs say enter to wish is would as this they into and is, that looking at Adam first for

And be in constant and evaluate them, so, programs assistance to discussions we're most which would looking constant in and appropriate. helping

Unidentified Analyst

very tag one more. maybe That's I'll on helpful. great. just Okay,

be Amgen any they for what's could deal, forward realized? remind other economy should Just the stuff us going and you milestone the

Adam Gridley

Sure.

So, I'll start.

are potential in So, we still the This activities typical received the north milestones but our research certain as well that by conducted the process for development of teams receive the in associated regulatory an are payment did milestones in way, we of of December. to as upfront course confidential, for relates reimbursement there's back $XXX Israel announce milestones with development and has that well. as it we well specific as Along also million there any progress.

continue will positive well. to to as a provide So, financial a but as this that updates from expecting move funding perspective, non-dilutive outcome, we'll we're and will continue we hopefully forward we provide be very

Unidentified Analyst

Okay, on progress. and the again, great, thanks, congrats

Adam Gridley

Yale Thank Excellent. you, [ph].

Operator

you. the call back Thank for remarks. now closing will turn Adam, I to

Adam Gridley

to taking with appreciate Operator, time you look support, attending providing over update your and our targeted an of you, call. and Thank we to call our Thank day. many to Have this join few for quarter excellent to you. continued our and patients, and our investors, for the analyst investor We next meeting also third our conferences morning thanks November. everyone months, on forward the an

Operator

conference. today's concludes This

your You participation. at disconnect Thank your time. you this may for lines

Entera Bio (ENTX) 20 Aug 192019 Q2 Earnings call transcript